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OBJECTIVES We sought to relate left ventricular ejection fraction (EF), end-systolic volume index (ESVI)
and infarct size (IS), as measured in a single randomized trial, to six-month mortality after
myocardial infarction (MI) treated with thrombolysis.
BACKGROUND These three prognostic indicators have never been compared in the same study group.
METHODS Radionuclide angiographic and single-photon emission computed tomographic sestamibi
measurements of IS were performed in 1,194 and 1,181 patients, respectively, of the 2,948
patients enrolled in the Collaborative Organization for RheothRx Evaluation (CORE) trial.
Ejection fraction, ESVI and IS, as measured by central laboratories in these radionuclide
substudies, were tested for their association with six-month mortality.
RESULTS Ejection fraction (n  1,137; p  0.0001), ESVI (n  945; p  0.055) and IS (n  1,164;
p  0.03) were all associated with six-month mortality. Each of these measurements was
significantly correlated with the other two, regardless of MI location. In an “overlap” group
of 753 patients (25.5% of the population; 13 deaths) in whom all three measurements were
available, EF (p  0.001) was a stronger predictor than ESVI (p  0.005) or IS (p  0.01).
Neither of the other two measurements added independent prognostic information. The
highest risk subgroup (EF  30%) had an 11% six-month mortality, but comprised only 95
patients (8.3%).
CONCLUSIONS Ejection fraction, ESVI and IS measurements performed one to two weeks after MI can each
predict six-month mortality. Ejection fraction was superior to the other two measurements.
However, this study had limited power to detect independent significance of ESVI or
IS. (J Am Coll Cardiol 2002;39:30–6) © 2002 by the American College of Cardiology
The probability of death after myocardial infarction (MI) is
substantially determined by the resulting cumulative left
ventricular (LV) structural and functional derangement (1).
Ejection fraction (EF) measured at the time of hospital
discharge after MI has long been recognized as a strong
predictor of subsequent short- and long-term mortality
(2,3). In the thrombolytic era, post-MI survival has im-
proved (4–7), but EF remains a strong prognosticator (8).
Both end-systolic volume index (ESVI) and infarct size
(IS) are alternatives to EF. Using contrast ventriculography,
White et al. (9) demonstrated that ESVI, measured one to
two months after MI, was superior to EF for the prediction
of long-term survival. Direct measurement of IS using
technetium-99m (99mTc) sestamibi single-photon emission
computed tomography (SPECT) correlates closely with the
amount of fibrosis in human hearts (10), predicts subse-
quent mortality (11) and is less affected by LV loading.
The purpose of this study was to relate EF, ESVI and IS
measurements obtained between days 6 and 16 after MI
treated by thrombolysis to mortality at six months. The
Collaborative Organization for RheothRx Evaluation
(CORE) was a prospective, randomized, double-blinded,
placebo-controlled trial of a novel therapy (Poloxamer 188)
adjunctive to thrombolysis (12). In CORE, Poloxamer 188
had no impact on six-month mortality in 2,948 patients or
on IS, EF or ESVI (each measured in substudies of 1,000
patients by radionuclide techniques). This large clinical trial
with a neutral treatment effect is an excellent setting in
which to evaluate and compare these three noninvasive
radionuclide measurements.
METHODS
Study protocol. Subsets of clinical centers participating in
CORE also participated in one or two radionuclide sub-
studies: 1) radionuclide angiography for measurement of EF
and absolute, count-based LV volumes; and 2) rest 99mTc-
sestamibi SPECT imaging for measurement of IS.
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Patient inclusion criteria for CORE (12) included symp-
toms consistent with acute MI and 1 mm of ST segment
elevation in at least two contiguous leads or left bundle
branch block. Exclusion criteria were age 21 years, onset
of symptoms 12 h before randomization, emergency
revascularization, serum creatinine220 mol/l, pregnancy
or child-bearing potential, previous exposure to RheothRx
and treatment with an investigational drug or device within
the previous seven days. Both radionuclide substudies were
conducted between days 6 and 16 (inclusive) after MI.
Radionuclide angiography. If preceded by 99mTc-
sestamibi SPECT, radionuclide angiography was conducted
at least 48 h later. Red blood cells were labeled in vitro using
30 mCi of 99mTc sodium pertechnetate, according to a
method either locally established or prescribed per the
protocol, providing high (90%) labeling efficiency.
We have previously described and validated the count-
based method for absolute LV volume measurement (13),
using a skin marker for “tissue depth” and a venous blood
sample. The unprocessed images were sent to a central
laboratory at the Toronto Hospital for analysis.
Ejection fraction was determined using a highly repro-
ducible, semi-automated, second-derivative LV edge-
detection and count-determination method, as previously
reported from our laboratory (14). The ESVI was calculated
as: LV end-diastolic volume  (1  ejection fraction)/body
surface area.
Technetium-99m sestamibi SPECT. Each site was first
required to qualify for this substudy by the acquisition of a
cardiac phantom study to ensure the accuracy of a desig-
nated SPECT imaging system for IS (15). If preceded by
radionuclide angiography, 99mTc-sestamibi SPECT was
conducted at least 24 h later.
The procedures for image acquisition, processing and
interpretation have been reported previously (16). To sum-
marize, patients received 20 to 30 mCi of 99mTc-sestamibi
at rest, and SPECT was performed 1 h later using a rotating
gamma camera with a low-energy, all-purpose collimator.
Raw projection images were forwarded to the IS central
laboratory at the Mayo Clinic. Processing and reconstruc-
tion of SPECT images were performed using backprojec-
tion and a Ramp-Hanning filter. Infarct size was calculated
as the summed proportion of points 60% of peak counts,
expressed as a percentage of the LV. This technique has
been extensively validated (17).
Clinical follow-up. All surviving patients were contacted
for clinical follow-up periodically and at six months. Serious
adverse events, including death, were reported by investiga-
tors within 24 h to monitors under contract to the study
sponsor. These events were adjudicated blindly by an
independent Central Validation Committee.
Statistical methods. The relationship of six-month mor-
tality to the radionuclide outcome measurements, analyzed
as continuous variables, was examined using logistic regres-
sion analysis, where the dependent variable was survival or
death at six months. Stepwise logistic regression analysis
was performed to evaluate the additional explanatory power
of multiple outcome measurements.
The association between pairs of radionuclide measure-
ments was assessed by linear regression analysis, with and
without adjustment for the co-variates of previous MI and
MI location. The EF results were stratified for display in
five ranges (categories), which had been selected a priori, in
accordance with those used in the Thrombolysis in Myo-
cardial Infarction trial (TIMI-2) (8). Similarly, four ranges
(categories) of ESVI were determined a priori, using values
derived from those reported by White et al. (9).
Four categories of IS were likewise established a priori,
but de novo. A previous investigation demonstrated a low
mortality for IS12% of the LV—the first breakpoint (11).
Similarly, maintenance of normal EF was known to be
associated with IS 20%, which was the second breakpoint
(18). The third breakpoint for the largest infarcts, 35% of
the LV, was based on clinical experience.
RESULTS
Study patients. Of 2,948 patients enrolled in CORE,
1,194 (40.5%) underwent radionuclide angiography. Of
these 1,194 patients, 1,137 (95.2%) had technically satisfac-
tory studies for determination of EF, and 945 (79.1%) had
technically satisfactory studies for determination of ESVI.
Similarly, 1,181 patients (39.6%) of the patients enrolled in
CORE underwent 99mTc-sestamibi SPECT; of these,
1,164 (98.6%) had technically satisfactory studies for deter-
mination of IS. All three radionuclide outcome measure-
ments were obtained in an “overlap” group of 753 patients
(25.5% of the study population). Six-month follow-up was
obtained in 2,841 (96.4%) of the patients enrolled, and 725
patients (96.3%) in the “overlap” group.
Patients in the radionuclide angiographic substudy with
technically satisfactory studies (n  1,137) were compared
with all other patients (n 1,577) who were alive on day 16
and thus “eligible” for the radionuclide substudies (Table 1).
Of these 1,577 patients, a subset of 281 was enrolled at sites
participating in the radionuclide angiographic substudy
(Table 1, last column). Six-month mortality was signifi-
cantly lower in the radionuclide angiographic substudy
Abbreviations and Acronyms
CORE  Collaborative Organization for RheothRx
Evaluation
EF  ejection fraction
ESVI  end-systolic volume index
IS  infarct size
LV  left ventricular or ventricle
MI  myocardial infarction
SPECT single-photon emission computed tomography
99mTc  technetium-99m
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group, suggesting that “sicker” patients were excluded from
the substudy.
Relationships among radionuclide measurements. The
three radionuclide measurements were significantly associ-
ated with each other. The strongest correlation was between
ESVI and EF (r  0.78, p  0.0001) (Fig. 1). This
correlation was predictable, as EF is employed in the
calculation of ESVI. However, IS was significantly corre-
lated with both EF (r  0.67, p  0.0001) (Fig. 2) and
ESVI (r  0.57, p  0.0001), although it is determined
from a different radionuclide measurement. Infarct location
was entered as a co-variate in each of these analyses and was
not significant.
Univariate relationship of radionuclide measurements to
six-month mortality. There was a strong inverse relation-
ship between six-month mortality and EF (chi-square
value  44.3, p  0.0001) (Fig. 3). The highest risk
subgroup was composed of 95 patients with EF  30%;
there were 10 deaths in this subgroup (11% mortality rate).
In contrast, there were only four deaths in the 603 patients
with EF 50% (0.7% mortality rate). Ejection fraction was
an important predictor of mortality, independent of the
worst Killip class. Figure 4 shows a direct relationship
between mortality and ESVI (chi-square value  7.62, p 
0.055). The highest risk subgroup (ESVI  70 ml/m2)
included 74 patients and three deaths (4.1% mortality rate).
Figure 5 illustrates a direct relationship between six-month
mortality and IS (chi-square value  9.05, p  0.03). The
highest risk subgroup (IS 35%) included 266 patients and
12 deaths (4.5% mortality rate). Infarct size was an impor-
tant predictor of mortality in both anterior and non-anterior
infarcts.
Multivariate logistic regression. Although the previous
analyses included all patients with available measurements
for each of the three individual measurements, the relation-
ship between six-month mortality and EF, ESVI and IS
measurements was examined in a separate analysis limited to
only the 753 patients (the “overlap” group) who had all three
of these measurements obtained (Table 2). Each of the
three measurements was highly predictive of six-month
mortality. Of the three, EF was the strongest predictor.
Once EF was considered, ESVI and IS were no longer
significantly related to six-month mortality, indicating that
they offer no additional predictive power. However, in a
model containing either ESVI or IS, EF added significantly
to its predictive power. Tables 3 and 4 show six-month
mortality for patient subgroups defined by EF and the
highest risk values of ESVI (70 ml/m2) and IS (35%).
Neither ESVI nor IS had any appreciable effect.
DISCUSSION
Clinical significance. There are no previously reported
data to describe, quantify and compare the prognostic value
Table 1. Clinical Characteristics of Patients Included and Not
Included in RNA Substudy
RNA
Substudy
(n  1,137)
No RNA/Alive
on Day 16
(n  1,577)
No RNA But
RNA Site/Alive
on Day 16
(n  281)
Male (%) 78.4 78.5 80.7
Mean age (yrs) 58.7 58.8 59.4
Mean time to
treatment (h)
3.5 3.6 3.7
Previous MI (%) 16.7 16.9 17.4
Diabetes (%) 17.2 13.4 16.0
Congestive heart
failure (%)
2.1 3.1 4.6
Anterior MI (%) 37.9 42.4 44.8
Six-month mortality
(%)
1.9 4.2* 6.8†
*p  0.0006, †p  0.0001 versus RNA substudy.
MI  myocardial infarction; RNA  radionuclide angiography.
Figure 1. Left ventricular (LV) end-systolic volume index and LV ejection fraction in 909 patients with both measurements. There was a highly significant
correlation (r  0.78, p  0.001) between the two.
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of IS, EF and ESVI—three safe, widely available and highly
reproducible radionuclide measurements—in survivors of
MI treated with thrombolysis. Our results demonstrate that
each of these three radionuclide measurements can predict
the likelihood of death in such patients, despite low overall
mortality. This study also demonstrates that these radionu-
clide measurements are highly suitable for multicenter
clinical trials, as the data reported here originated from
hospitals engaged in a clinical trial undertaken in 16
countries on five continents.
The study group was generally a low-risk cohort. Low
six-month mortality (5%) after hospital discharge was
observed not only within the patient subgroups defined by
availability of the radionuclide measurements, but also in
the larger groups that did not undergo SPECT imaging or
radionuclide angiography. This low mortality reflects the
selection process for thrombolytic therapy (19), the benefit
of thrombolytic therapy (8,17) and the favorable effect of
other contemporary MI management strategies (4–7). The
highest mortality in the radionuclide subgroups was found
in patients with the lowest EF (30%). There were 10
deaths among 95 patients (11%) in this category, which
comprised only 8.3% of all patients with EF measurements.
Previous studies. The six-month all-cause mortality in
CORE subjects stratified according to EF categories is
virtually coincident with analogous one-year cardiovascular
Figure 2. Infarct size and left ventricular (LV) ejection fraction in the 872 patients with both measurements. There was a highly significant correlation (r
0.67, p  0.001) between the two.
Figure 3. Six-month mortality for different values of left ventricular (LV) ejection fraction, shown with 95% confidence intervals.
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mortality reported in TIMI-2 (8). The mortality of patients
in whom EF was not measured was also similar (6.2% in
TIMI-2, 4.1% in CORE). Within each category of EF,
patients in this study and in TIMI-2 had much lower
mortality than that observed in the older Multicenter
Postinfarction Trial (2), again reflecting the effects of
selection for thrombolytic therapy, as well as the benefits of
contemporary therapy. Ejection fraction provided important
prognostic information that was independent of Killip class.
There are few published reports on the prognostic value
of ESVI after MI treated by thrombolysis. Our data suggest
that ESVI is comparable to, but not better than, EF as a
prognostic indicator. In contrast, White et al. (9) demon-
strated that within categories of EF, there was significant
additional prognostic information when patients were sec-
ondarily stratified according to a “large” or “small” ESVI.
Unlike White et al. (9), we did not observe higher mortality
in patients with the lowest EF who had greater ESVI.
Figure 4. Six-month mortality for different values of left ventricular (LV) end-systolic volume index, shown with 95% confidence intervals.
Figure 5. Six-month mortality for different values of infarct size, shown with 95% confidence intervals.
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The difference in our results, compared with those of
White et al. (9), has many potential explanations. This study
enrolled patients undergoing thrombolysis; White et al. (9)
studied a broader, more general post-MI population. This
study used radionuclide angiography to measure ESVI;
White et al. (9) used contrast ventriculography, which is
likely more accurate. This study evaluated patients on days
6 to 16 after MI; White et al. (9) evaluated patients four to
eight weeks after MI. This study followed patients for six
months; White et al. (9) followed them for 78 32 months.
This study was performed in the 1990s, when the use of
angiotensin-converting enzyme inhibitors after MI was
more common than in the early 1980s, when White et al.
(9) enrolled their patients.
The prognostic value of IS reported here in 1,164 patients
confirms the results previously reported in two small series:
a single-center study of 274 patients (11) and a multicenter
study of 249 patients (20). Because EF and ESVI are
influenced by preload, afterload and myopathic processes, as
well as the extent of MI, IS might conceivably be a superior
prognostic indicator. However, our results do not support
this hypothesis.
Each of the three measurements was closely correlated
with one another. A close correlation between IS and both
EF and ESVI has been reported previously in small,
carefully controlled, single-center series (21,22). Our results
confirm these findings in a much larger, less selected,
multicenter cohort. The correlation between ESVI and EF
is expected, as the EF, which is directly measured, is
employed in the calculation of ESVI. The results of the
multivariate logistic regression analysis in the “overlap”
group of 753 patients are consistent with the close associa-
tion of the three measurements, although EF appears
superior with respect to its prognostic power.
Study limitations. These data have several limitations. As
previously indicated, “sicker” patients appear to have been
less likely to participate in these substudies. The ESVI
measured by radionuclide angiography is likely to be less
accurate than that obtained by contrast ventriculography (9)
or electron beam computed tomography (21). Although this
is the largest reported post-MI series of IS measurements, as
well as one of the largest of EF measurements, the power of
this study was still modest, owing to the limited number of
events. In the 753 patients in the overlap group, there were
only 13 deaths within six months. Given this modest
number of events, the power to detect independent signif-
icance of two of the radionuclide measurements was very
limited.
Despite these limitations, these data demonstrate that
each one of these three radionuclide measurements, per-
formed one to two weeks after MI treated with thrombol-
ysis, can predict mortality over the next six months. They
are closely associated and provide similar prognostic infor-
mation, although EF is superior in this regard.
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Table 3. Six-Month Mortality by Left Ventricular Ejection
Fraction and End-Systolic Volume Index
Ejection
Fraction
ESVI*
All Patients<70 >70
30% 4/39 (10.3%) 3/41 (7.3%) 10/95 (10.5%)
30–39% 3/129 (2.3%) 0/26 (0%) 3/181 (1.7%)
40% 6/703 (0.9%) 0/7 (0%) 8/861 (0.9%)
All 13/871 (1.5%) 3/74 (4.0%)† 21/1,137 (1.8%)
*Only 945 subjects had ESVI measured (ml/m2). †After stratification by EF, there
was no significant difference between the ESVI subgroups.
Abbreviations as in Table 2.
Table 4. Six-Month Mortality by Ejection Fraction and
Infarct Size
Ejection
Fraction
Infarct Size*
All Patients<35% >35%
30% 2/12 (16.7%) 5/62 (8.1%) 7/74 (9.5%)
30–39% 1/66 (1.5%) 0/76 (0%) 1/142 (0.7%)
40% 6/592 (1.0%) 0/61 (0%) 6/653 (0.9%)
All patients 9/670 (1.3%) 5/199 (2.5%) 14/869 (1.6%)
*Expressed as percentage of the left ventricle.
Table 2. Comparison of the Prognostic Value of the Three Measurements in the “Overlap”
Group (n  753)
Radionuclide Variable
Univariate Analysis Multivariate Analysis*
Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value
EF (0.01 change) 0.926 0.884 0.0011 — — —
0.970
ESVI 1.021 1.006 0.0055 0.998 0.971 0.867
1.036 1.025
IS 1.033 1.008 0.0107 1.009 0.968 0.894
1.060 1.037
*Adjusted for ejection fraction.
CI  confidence interval; EF  ejection fraction; ESVI  end-systolic volume index; IS  infarct size.
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